Wockhardt drug discovery gets fast track approval from USFDA

Wockhardt today said its new drug discovery programme in anti-infective research has received a major boost after two of its drugs, WCK 771 and WCK 2349, received the Qualified Infectious Disease Product (QIDP) status from the US FDA.

This is the first instance of an Indian pharmaceutical company receiving a QIDP status, Wockhardt said in a release issued here.

"This is indeed a proud moment for us. Not only does the status allow for fast track review of our drug application, it also grants a five year extension to the drug patents in USA, which is a major support for the commercial aspect of the drug. These drugs will be entering in their global Phase-3 clinical trials early next year," Wockhardt Founder Chairman and Group CEO Habil Khorakiwala said.

A QIDP status is granted to drugs, which act against pathogens that have a high degree of unmet need in their treatment and are identified by the Centre for Disease Control, USA - a top US government health and safety body.

QIDP status allows for fast track review of the drug application by US FDA paving way for an early launch.

Globally, there is a significant antibiotic vacuum due to dual impact of rise in new resistant pathogens and declining research in this area, the statement said.

Over the years, Wockhardt has developed a strong anti-infective program which focuses on development of drugs which target this antibiotic gap.

Both WCK 771 and WCK 2349 act against one of the globally rising class of pathogens, MRSA (Methicillin-resistant Staphylococcus Aureus) which causes a range of diseases from the skin infection to severe respiratory infections.

In case of severe infections like Hospital Acquired Pneumonia (HAP), current medical cure has a very limited reach causing a high unmet need and mortality.

EDITORIAL OF THE DAY

  • Census shows urgent steps are needed to dispel rural despair

    The much delayed Socio-Economic and Caste Census, 2011, has finally seen the light of day, and going by its conclusions, it couldn’t have come a day

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Urs Schoettli

Economic integration in east Asia

As trade agreements within a global framework have become increasingly ...

Rajgopal Nidamboor

Up the ante of your conscious existence

It sounds cryptic, but is not as complex as it ...

Gautam Gupta

The ‘fake’ issue needs to be taken seriously

E-commerce players are witnessing unbelievable growth globally. Competition is increasing ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture